TAG Mail 27th May 2015

TAG MEETINGS
- DUE Support Group meeting, Wednesday 3 June 2015 3-5pm, NSW TAG office/teleconference

TAG ACTIVITIES
- Email discussions
  -- Use of smart pumps with drug libraries (closes 5 June 2015)
  -- Prescribing of contrast media (closes 18 June 2015)

- Drug Shortage: Stock management principles need to be utilised for metoclopramide 10mg/2mL injection BP while distributor/supplier stock of the Pfizer product is depleted (and only the iNova product is available). This disruption is estimated to resolve by mid-June.

- CATAG
  -- Position Statement for the use of complementary and alternative medicines
  http://www.catag.org.au

TAG WEBSITE
Nil

REPORTS AND PUBLICATIONS - AUSTRALIA
**AIHW
Development of a national education and training data standards strategy and implementation plan

**TGA
- TGA presentation given at the Sydney Children's Hospital Network Research Governance, 31 March 2015 - an overview of the TGA's role in controlling access to unapproved therapeutic goods, including in clinical trials
- Information for registered users of the Australian Adverse Drug Reaction Reporting System
- Natalizumab and melanoma; Final update - no definite link established
**REPORTS AND PUBLICATIONS - INTERNATIONAL**

**EMA**
- First-in-class treatment to lower cholesterol; EMA has recommended authorising Repatha (evolocumab)
- New treatment option recommended for patients with advanced melanoma, Keytruda (pembrolizumab)
- New treatment option for patients with advanced lung cancer, Nivolumab BMS (nivolumab)
- EMA recommends treatment for rare cancer in children, Unituxin (dinutuximab)
- EMA recommends Imbruvica (ibrutinib) for the treatment of Waldenström’s macroglobulinaemia, Imbruvica (ibrutinib)

**Health Improvement Scotland - NHS boards and Area DTCs**
Biosimilar medicines: A national prescribing framework

**MEDICATION SAFETY**

**EMA**
Updated advice on use of high-dose ibuprofen

**FDA**
- FDA Drug Safety Communication: FDA cautions about dose confusion and medication errors for antibacterial drug Zerbaxa (ceftolozane and tazobactam)
  http://www.fda.gov/Drugs/DrugSafety/ucm445919.htm
- FDA Drug Safety Podcast: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood

**ISMP**
The absence of a drug-disease interaction alert leads to a child’s death
**MHRA**

- Drug Safety Update, May 2015
  -- Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone
  -- Pomalidomide (Imnovid▼): risks of cardiac failure, interstitial lung disease and hepatotoxicity
  -- Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded
  -- Fingolimod (▼Gilenya): first reported case of progressive multifocal leukoencephalopathy in a multiple sclerosis patient taking fingolimod
    https://assets.digital.cabinet-office.gov.uk/media/555c338ced915d7ae5000007/Gilenya_DHPC_sent_29_April.pdf
  -- Topical ketoprofen and risk of photosensitivity reactions: reminder of risk minimisation measures

**NPS-MedicineWise**

Reducing paracetamol misuse

**PAPERS OF INTEREST**

**Ann Intern Med**

- Longer Versus Shorter Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis
  http://annals.org/article.aspx?articleid=2297227
- Development of an "infusion pump safety score"
  http://dx.doi.org/10.2146/ajhp140421

**BMJ**

Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
http://www.bmj.com/content/350/bmj.h2135

**Circulation**
Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis
http://circ.ahajournals.org/content/early/2015/05/15/CIRCULATIONAHA.114.013267.abstract

**Clin Transplant**
Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart-transplant patients

**Eur J Hosp Pharm**
- A 2-year retrospective review of vial sharing options for the compounding of cytotoxics
http://ejhp.bmj.com/content/22/3/161.abstract
- Evaluation of eight drug interaction databases commonly used in the German healthcare system
http://ejhp.bmj.com/content/22/3/165.abstract

**JAMA**
Stroke Prevention in Atrial Fibrillation: A Systematic Review

**JAMA Internal Medicine**
Tools to Promote Shared Decision Making in Serious Illness: A Systematic Review

**JAMA Ophthalmology**
Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants: Systematic Review and Meta-analysis

**J Thromb Thrombolysis**
Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations

**Lancet**
- Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62459-4/abstract
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
http://www.thelancet.com/journals/lancet/issue/current
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
http://www.thelancet.com/journals/lancet/issue/current

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial
http://www.thelancet.com/journals/lancet/issue/current

**Lancet - Haematology**
Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial

**NEJM**
Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection

**CONSULTATIONS**
**ACQSHC**
Consultation on draft Delirium and Hip Fracture Care Clinical Care Standards. Closes 3 July 2015

**TGA**
- Orphan drugs program (closes on 15 June 2015)
- Draft OTC medicine monographs for Bromhexine hydrochloride; Dextromethorphan hydrobromide; Laxatives: Docusate sodium and/or sennosides; Hand sanitisers (closes on 11 June 2015)

**OTHER NEWS**
**ACSQHC**
The Commission has requested that any hospital orders for the ‘Consumer Information wallet’ jointly developed with NPS be sent to medsafety@safetyandquality.gov.au by 29 May 2015 stating the number of wallets required, the contact person and the delivery address, including area or department of the ordering hospital. Information about the wallets can be found at this link:
http://www.safetyandquality.gov.au/our-work/medication-safety/medication-
reconciliation/consumer-resources/

**Centre for Health Systems and Safety Research-AIHI**
Position: Research Fellow for NHMRC partnership grant “Delivering safe and effective care for children in hospital with eHealth systems”, 3 year fixed-term. Applications close 7th June 2015

**SSWAHS**
Position: Maternity relief Director of Pharmacy, Canterbury Hospital, a 200+ bed metropolitan hospital in Inner West Sydney. Applications close 5 June 2015

**UPCOMING EVENTS** (new additions in **bold**)

**Medscape**
CME/CE Live Event. The Biosimilar **Matrix: The Impact of Biosimilars in Managing Neutropenia**. Sunday, May 31, 2015 7:00 PM to 8:30 PM (Chicago time)

**CEBM (Centre for Evidence-Based Medicine)**
‘Harms in Health Care’ Five Day Workshop chaired by Jeffrey Aronson, 22-26 June 2015, Oxford, UK. NB Small registration numbers possible so don’t delay
http://www.cebm.net/harms-health-care/

**Change Champions**

**The AlfredTC-IFEM**

**ISQUA**
‘Building Quality and Safety into the Healthcare System’, 4-7 October 2015, Doha, Qatar. Early bird registrations close 15th July 2015

**AHRQ**
Agency for Healthcare Research and Quality (AHRQ) research conference, 4-6 October, 2015, Crystal City, Virginia USA
Health care research and policy sessions on improving quality, safety, access and value in health care

*SHPA
Medicines Management 2015, 3-6 December 2015, Melbourne Convention Centre.
Call for abstracts now open - closes Friday 17 July 2015
http://mm2015shpa.com/